---
category: news
title: "Alzheimer’s drug shows promise in slowing cognitive decline"
excerpt: "An experimental Alzheimer’s drug, called lecanemab, has successfully met its primary endpoints in a Phase III trial, which found it slows cognitive decline and improves daily activities. Nearly 50 million people worldwide are living with Alzheimer’s ..."
publishedDateTime: 2022-10-12T11:05:00Z
originalUrl: "https://www.biotechniques.com/neuroscience/alzheimers-drug-shows-promise-in-slowing-cognitive-decline/"
webUrl: "https://www.biotechniques.com/neuroscience/alzheimers-drug-shows-promise-in-slowing-cognitive-decline/"
type: article

provider:
  name: BioTechniques
  domain: biotechniques.com

topics:
  - Microsoft AI
  - AI

images:
  - url: "https://www.biotechniques.com/wp-content/uploads/2022/10/neurons.png"
    width: 800
    height: 345
    isCached: true

secured: "UoYdaC6aArfflmnBmHJ6mrMtCY/gZTkI4iO0rrBRTViOU82hXa7OLqGk8uZ2jSkbJVCPbJ4WoOYKPd9wVrhkQuD1b7RUf3PFwFa/dEKTj2iVtUz9dABjO1Yruy7hy2V2WDmiIqs5WJyfz5gUQRO7Ct1hkgZ/EcmcK6j9Kwxjv78qU6NyLWyumY1ISwgpdp1kwDK8+rJaLnGIVE06J6ubEBgDA5Yyj3KllmbBhSg83oBjF/GBdEThnowxUCjpZ8r2Llq95tcp33CXDfiMOKAGJ2hmK5WHA1RO/3QvmVajsFNAKRxZ5zYg1Y4n+9/3IgMDgLBb+L8xxZhlKkq2D5LLDB58YBdLV6IVCSOBLipGg+M=;Y84aeK2ZH/EeHlZhjXtQDA=="
---

